Update on thrombotic thrombocytopenic purpura;Le purpura thrombotique thrombocytopénique acquis de l'adulte : actualités

Revue de Medecine Interne

Volumn 29, Issue 10, 2008, Pages 794-800

  Schleinitz, N ^a   Poullin, P ^a   Camoin, L ^a   Veit, V ^a   Bernit, E ^a   Mazodier, K ^a   Lefevre P ^a   Dignat George, F ^a   Kaplanski, G ^a   Durand, J M ^a   Harle J R ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

Author keywords

ADAMTS 13; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

RITUXIMAB; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

DIFFERENTIAL DIAGNOSIS; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PLASMAPHERESIS; PREVALENCE; RELAPSE; SHORT SURVEY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADRENAL CORTEX HORMONES; DIAGNOSIS, DIFFERENTIAL; HUMANS; PLASMA EXCHANGE; PLATELET AGGREGATION INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 52149100129     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.09.034     Document Type: Short Survey

References (49)

1. Moschowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease. Proc of the N Y Pathol Soc 24 (1924) 21-24
2. Furlan M., Robles R., and Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87 (1996) 4223-4234
3. Tsai H.M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87 (1996) 4235-4244
4. Furlan M., Robles R., Galbusera M., Remuzzi G., Kyrle P.A., Brenner B., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 (1998) 1578-1584
5. Tsai H.M., and Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 (1998) 1585-1594
6. Miller D.P., Kaye J.A., Shea K., Ziyadeh N., Cali C., Black C., et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology 15 (2004) 208-215
7. Rock G.A., Shumak K.H., Buskard N.A., Blanchette V.S., Kelton J.G., Nair R.C., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med 325 (1991) 393-397
8. Moake J.L. Thrombotic microangiopathies. N Engl J Med 347 (2002) 589-600
9. Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E., and Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276 (2001) 41059-41063
10. Fujikawa K., Suzuki H., McMullen B., and Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98 (2001) 1662-1666
11. Gerritsen H.E., Robles R., Lammle B., and Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98 (2001) 1654-1661
12. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 (2001) 488-494
13. Scheiflinger F., Knobl P., Trattner B., Plaimauer B., Mohr G., Dockal M., et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102 (2003) 3241-3243
14. Veyradier A., Obert B., Houllier A., Meyer D., and Girma J.P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 98 (2001) 1765-1772
15. Ferrari S., Scheiflinger F., Rieger M., Mudde G., Wolf M., Coppo P., et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109 (2007) 2815-2822
16. Coppo P., Wolf M., Veyradier A., Bussel A., Malot S., Millot G.A., et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 132 (2006) 66-74
17. Banno F., Kokame K., Okuda T., Honda S., Miyata S., Kato H., et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 107 (2006) 3161-3166
18. Rock G., Kelton J.G., Shumak K.H., Buskard N.A., Sutton D.M., and Benny W.B. Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian apheresis group. Br J Haematol 103 (1998) 1031-1036
19. Allford S.L., Hunt B.J., Rose P., and Machin S.J. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 120 (2003) 556-573
20. Sadler J.E., Moake J.L., Miyata T., and George J.N. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) (2004) 407-423
21. Schleinitz N., Ebbo M., Mazodier K., Poullin P., Bernit E., Veit V., et al. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS-13 inhibitor. Am J Hematol 82 (2007) 417-418
22. Andres E., Affenberger S., Federici L., and Korganow A.S. Pseudo-thrombotic microangiopathy related to cobalamin deficiency. Am J Med 119 (2006) e3
23. Zakarija A., and Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 31 (2005) 681-690
24. Henon P. [treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study]. Presse Med 20 (1991) 1761-1767
25. Coppo P., Bussel A., Charrier S., Adrie C., Galicier L., Boulanger E., et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 82 (2003) 27-38
26. Rock G., Anderson D., Clark W., LeBlond P., Palmer D., Sternbach M., et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 129 (2005) 79-86
27. Raife T.J., Friedman K.D., and Dwyre D.M. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: Reconsideration of treatment with cryopoor plasma. Transfusion 46 (2006) 74-79
28. Hull M.J., and Eichbaum Q.G. Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Clin Adv Hematol Oncol 4 (2006) 210-214
29. Darabi K., and Berg A.H. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 125 (2006) 592-597
30. George J.N., Woodson R.D., Kiss J.E., Kojouri K., and Vesely S.K. Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the transfusion medicine/hemostasis clinical trials network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 21 (2006) 49-56
31. Bandarenko N., and Brecher M.E. United states thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 13 (1998) 133-141
32. Bennett C.L., Connors J.M., Carwile J.M., Moake J.L., Bell W.R., Tarantolo S.R., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342 (2000) 1773-1777
33. Centurioni R., Bobbio-Pallavicini E., Porta C., Rodeghiero F., Gugliotta L., Billio A., et al. Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian cooperative group for TTP. Haematologica 80 (1995) 325-331
34. Dervenoulas J., Tsirigotis P., Bollas G., Koumarianou A.A., Pappa V., Mantzios G., et al. Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases. Acta Haematol 105 (2001) 204-208
35. Shumak K.H., Rock G.A., and Nair R.C. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian apheresis group. Ann Intern Med 122 (1995) 569-572
36. Bell W.R. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: Frequency, pathogenesis, and meaning. Semin Hematol 34 (1997) 134-139
37. Ahmad A., Aggarwal A., Sharma D., Dave H.P., Kinsella V., Rick M.E., et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 77 (2004) 171-176
38. Gutterman L.A., and Stevenson T.D. Treatment of thrombotic thrombocytopenic purpura with vincristine. JAMA 247 (1982) 1433-1436
39. Durand J.M., Lefevre P., Kaplanski G., Telle H., and Soubeyrand J. Vincristine for thrombotic thrombocytopenic purpura. Lancet 340 (1992) 977-978
40. Welborn J.L., Emrick P., and Acevedo M. Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresis. Am J Hematol 35 (1990) 18-21
41. Ferrara F., Annunziata M., Pollio F., Palmieri S., Copia C., Mele G., et al. Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. Ann Hematol 81 (2002) 7-10
42. Bobbio-Pallavicini E., Porta C., Centurioni R., Gugliotta L., Vianelli N., Tacconi F., et al. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian cooperative group for TTP. Eur J Haematol 52 (1994) 222-226
43. Chemnitz J., Draube A., Scheid C., Staib P., Schulz A., Diehl V., et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 71 (2002) 105-108
44. Gutterman L.A., Kloster B., and Tsai H.M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 28 (2002) 385-391
45. Zheng X., Pallera A.M., Goodnough L.T., Sadler J.E., and Blinder M.A. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 138 (2003) 105-108
46. Reddy P.S., Deauna-Limayo D., Cook J.D., Ganguly S.S., Blecke C., Bodensteiner D.C., et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 84 (2005) 232-235
47. Herbei L., and Venugopal P. Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clin Adv Hematol Oncol 4 (2006) 215-217
48. Fakhouri F., Vernant J.P., Veyradier A., Wolf M., Kaplanski G., Binaut R., et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 106 (2005) 1932-1937
49. Scully M., Cohen H., Cavenagh J., Benjamin S., Starke R., Killick S., et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136 (2007) 451-461